Mater Misericordiae University Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (12)

2023

  1. EFOMP policy statement NO. 19: Dosimetry in nuclear medicine therapy – Molecular radiotherapy

    Physica Medica, Vol. 116

  2. The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease

    Arthritis and Rheumatology, Vol. 75, Núm. 10, pp. 1703-1713

  3. The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 10, pp. 1248-1257

2022

  1. Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction

    Arthritis Care and Research, Vol. 74, Núm. 10, pp. 1649-1658

  2. Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery

    BJS Open, Vol. 6, Núm. 1

2021

  1. Flare rate thresholds for patient assessment of disease activity states in Gout

    Journal of Rheumatology, Vol. 48, Núm. 2, pp. 293-298

2020

  1. Sepsis at ICU admission does not decrease 30-day survival in very old patients: a post-hoc analysis of the VIP1 multinational cohort study

    Annals of Intensive Care, Vol. 10, Núm. 1

2018

  1. Brief Report: Validation of a Definition of Flare in Patients With Established Gout

    Arthritis and Rheumatology, Vol. 70, Núm. 3, pp. 462-467

  2. Correction to: Withholding or withdrawing of life-sustaining therapy in older adults (≥ 80 years) admitted to the intensive care unit (Intensive Care Medicine, (2018), 44, 7, (1027-1038), 10.1007/s00134-018-5196-7)

    Intensive Care Medicine

  3. Withholding or withdrawing of life-sustaining therapy in older adults (≥ 80 years) admitted to the intensive care unit

    Intensive Care Medicine, Vol. 44, Núm. 7, pp. 1027-1038

2017

  1. The impact of frailty on ICU and 30-day mortality and the level of care in very elderly patients (≥ 80 years)

    Intensive Care Medicine, Vol. 43, Núm. 12, pp. 1820-1828

2015

  1. Imaging as an outcome measure in gout studies: Report from the OMERACT gout working group

    Journal of Rheumatology, Vol. 42, Núm. 12, pp. 2460-2464